Literature DB >> 30818924

[Research progress of magnetic resonance imaging in hepatocellular carcinoma].

H X Zhang1, J K Li2, M S Wang2, Y Z Wang2, J Q Lei2.   

Abstract

Hepatocellular carcinoma (HCC) is the most common malignant tumors of liver. Rational treatment in early stage of HCC can significantly increase the survival rate of patients. Detection of early-stage liver lesions through diffusion-weighted imaging, diffusion kurtosis imaging, incoherent motion within voxels, magnetic resonance spectroscopy imaging, dynamic contrast-enhanced imaging, or other functional imaging can accurately evaluate grade of malignancy and guide towards the curative effect of different treatment schemes. Volumetric interpolated breath-hold examination (VIBE) with three techniques, namely, CAIPIRINHA, Dixon, and TWIST, i.e., CDT-VIBE sequence can provide multiple sets of arterial phase images in a short time, and detect small foci transient enhancement that cannot be detected by other examinations, and the differences in initial enhancement phase of apparent lesions are of great significance for suggesting hemodynamic characteristics. In addition, magnetic resonance imaging predicts microvascular invasion of HCC, i.e., indirectly predicts HCC lesions recurrence rate, and overall survival time after liver transplantation. This article reviews the current research progress of magnetic resonance imaging technology in HCC.

Entities:  

Keywords:  Carcinoma, hepatocellular; Magnetic resonance imaging; Microvascular invasion

Mesh:

Year:  2019        PMID: 30818924     DOI: 10.3760/cma.j.issn.1007-3418.2019.02.017

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  2 in total

1.  [Expression and significance of microRNA-125b in tongue squamous cell carcinoma].

Authors:  Jian Wang; Guang-Peng Yan; Chao Guo; Jun Li
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-02-01

2.  Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma.

Authors:  Xixi Mu; Yue Zhong; Xuan Zhang; Changjun Qu
Journal:  J Oncol       Date:  2022-05-13       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.